dc.identifier.citation | 1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. The Lancet.373(9669):1119-32.
2. Zhuge Y, Cheung MC, Yang R, Perez EA, Koniaris LG, Sola JE. Pediatric non-Wilms renal tumors: subtypes, survival, and prognostic indicators. J Surg Res. 2010;163(2):257-63.
3. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R. 2009 update on the classification of renal epithelial tumors in adults. International journal of urology : official journal of the Japanese Urological Association. 2009;16(5):432-43.
4. Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology. 2010;42(4):369-73.
5. Bruder E, Passera O, Harms D, Leuschner I, Ladanyi M, Argani P, et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol. 2004;28(9):1117-32.
6. Komai Y, Fujiwara M, Fujii Y, Mukai H, Yonese J, Kawakami S, et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res. 2009;15(4):1170-6.
7. Classe M, Malouf GG, Su X, Yao H, Thompson EJ, Doss DJ, et al. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas. Histopathology. 2017;70(7):1089-97.
8. Martignoni G, Pea M, Gobbo S, Brunelli M, Bonetti F, Segala D, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2009;22(8):1016-22.
9. Argani P, Ladanyi M. Translocation Carcinomas of the Kidney. Clinics in Laboratory Medicine.25(2):363-78.
10. Just PA, Letourneur F, Pouliquen C, Dome F, Audebourg A, Biquet P, et al. Identification by FFPE RNA-Seq of a new recurrent inversion leading to RBM10-TFE3 fusion in renal cell carcinoma with subtle TFE3 break-apart FISH pattern. Genes Chromosomes Cancer. 2016;55(6):541-8.
11. Argani P, Zhong M, Reuter VE, Fallon JT, Epstein JI, Netto GJ, et al. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers. Am J Surg Pathol. 2016;40(6):723-37.
12. de Jong B, Molenaar IM, Leeuw JA, Idenberg VJ, Oosterhuis JW. Cytogenetics of a renal adenocarcinoma in a 2-year-old child. Cancer Genet Cytogenet. 1986;21(2):165-9.
13. Eble JL, Sauter G, Epstein JI. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs WHO Classification of Tumours, Volume 7: World Health Organization; 2004.
14. Argani P, Hawkins A, Griffin CA, Goldstein JD, Haas M, Beckwith JB, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol. 2001;158(6):2089-96.
15. Moch H, International Agency for Research on C, Organización Mundial de la S. WHO classification of tumours of the urinary system and male genital organs. Lyon: International Agency for Research on Cancer (IARC); 2016.
16. Database G-HG. TFE3 Gene - Genecards [Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TFE3.
17. Database G-HG. TFEB Gene - Genecards [Available from: https://www.genecards.org/cgi-bin/carddisp.pl?gene=TFEB.
18. Martina JA, Diab HI, Lishu L, Jeong AL, Patange S, Raben N, et al. The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris. Sci Signal. 2014;7(309):ra9.
19. Huan C, Kelly ML, Steele R, Shapira I, Gottesman SR, Roman CA. Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity. Nat Immunol. 2006;7(10):1082-91.
20. Martina JA, Diab HI, Li H, Puertollano R. Novel roles for the MiTF/TFE family of transcription factors in organelle biogenesis, nutrient sensing, and energy homeostasis. Cell Mol Life Sci. 2014;71(13):2483-97.
21. Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, et al. TFEB links autophagy to lysosomal biogenesis. Science. 2011;332(6036):1429-33.
22. Steingrimsson E, Tessarollo L, Reid SW, Jenkins NA, Copeland NG. The bHLH-Zip transcription factor Tfeb is essential for placental vascularization. Development. 1998;125(23):4607-16.
23. Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34(10):1395-406.
24. Antonescu CR, Le Loarer F, Mosquera JM, Sboner A, Zhang L, Chen CL, et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer. 2013;52(8):775-84.
25. Folpe AL, Deyrup AT. Alveolar soft-part sarcoma: a review and update. J Clin Pathol. 2006;59(11):1127-32.
26. Huang W, Goldfischer M, Babayeva S, Mao Y, Volyanskyy K, Dimitrova N, et al. Identification of a novel PARP14-TFE3 gene fusion from 10-year-old FFPE tissue by RNA-seq. Genes Chromosomes Cancer. 2015;54(8):500-5.
27. Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, et al. Next-generation sequencing of translocation renal cell carcinoma reveals novel RNA splicing partners and frequent mutations of chromatin-remodeling genes. Clin Cancer Res. 2014;20(15):4129-40.
28. Kauffman EC, Ricketts CJ, Rais-Bahrami S, Yang Y, Merino MJ, Bottaro DP, et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nat Rev Urol. 2014;11(8):465-75.
29. Argani P. MiT family translocation renal cell carcinoma. Semin Diagn Pathol. 2015;32(2):103-13.
30. Rao Q, Williamson SR, Zhang S, Eble JN, Grignon DJ, Wang M, et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol. 2013;37(6):804-15.
31. Green WM, Yonescu R, Morsberger L, Morris K, Netto GJ, Epstein JI, et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol. 2013;37(8):1150-63.
32. Rao Q, Liu B, Cheng L, Zhu Y, Shi QL, Wu B, et al. Renal cell carcinomas with t(6;11)(p21;q12): A clinicopathologic study emphasizing unusual morphology, novel alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol. 2012;36(9):1327-38.
33. Argani P, Yonescu R, Morsberger L, Morris K, Netto GJ, Smith N, et al. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol. 2012;36(10):1516-26.
34. Rao Q, Zhang XM, Tu P, Xia QY, Shen Q, Zhou XJ, et al. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features. Int J Clin Exp Pathol. 2013;6(7):1452-7.
35. Camparo P, Vasiliu V, Molinie V, Couturier J, Dykema KJ, Petillo D, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32(5):656-70.
36. Argani P, Hicks J, De Marzo AM, Albadine R, Illei PB, Ladanyi M, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34(9):1295-303.
37. Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010;134(6):873-9.
38. Martignoni G, Gobbo S, Camparo P, Brunelli M, Munari E, Segala D, et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2011;24(10):1313-9.
39. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27(6):750-61.
40. Jeong CW, Cho JS, Lee M, Choi M, Song C, Lee S, et al. Comprehensive genetic characterization of TFE3-positive renal cell carcinoma. Journal of Clinical Oncology. 2018;36(6_suppl):635-.
41. Smith NE, Illei PB, Allaf M, Gonzalez N, Morris K, Hicks J, et al. t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases. Am J Surg Pathol. 2014;38(5):604-14.
42. Argani P, Lae M, Hutchinson B, Reuter VE, Collins MH, Perentesis J, et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29(2):230-40.
43. Altinok G, Kattar MM, Mohamed A, Poulik J, Grignon D, Rabah R. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations. Pediatr Dev Pathol. 2005;8(2):168-80.
44. Sukov WR, Hodge JC, Lohse CM, Leibovich BC, Thompson RH, Pearce KE, et al. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol. 2012;36(5):663-70.
45. Zhong M, De Angelo P, Osborne L, Paniz-Mondolfi AE, Geller M, Yang Y, et al. Translocation renal cell carcinomas in adults: a single-institution experience. Am J Surg Pathol. 2012;36(5):654-62.
46. Argani P, Olgac S, Tickoo SK, Goldfischer M, Moch H, Chan DY, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31(8):1149-60.
47. Klatte T, Streubel B, Wrba F, Remzi M, Krammer B, de Martino M, et al. Renal cell carcinoma associated with transcription factor E3 expression and Xp11.2 translocation: incidence, characteristics, and prognosis. Am J Clin Pathol. 2012;137(5):761-8.
48. Luo X, Luo B, Testa J, Patchefsky A, Dulaimi E. Conflicting Immunohistochemistry and Fluorescence In Situ Hybridization Results on Transcription Factor E3 Translocation Status in Renal Cell Carcinoma: A Case Report. American Journal of Clinical Pathology. 2018;150(suppl_1):S34-S5.
49. Classe M, Gregoire V, Malouf GG, Leroy X. Reply to 'Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas'. Histopathology. 2017;71(5):836-7.
50. Lee HJ, Shin DH, Noh GY, Kim YK, Kim A, Shin N, et al. Combination of immunohistochemistry, FISH and RT-PCR shows high incidence of Xp11 translocation RCC: comparison of three different diagnostic methods. Oncotarget. 2017;8(19):30756-65.
51. Inamura K, Fujiwara M, Togashi Y, Nomura K, Mukai H, Fujii Y, et al. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation. Am J Surg Pathol. 2012;36(1):35-42.
52. Ellis CL, Eble JN, Subhawong AP, Martignoni G, Zhong M, Ladanyi M, et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2014;27(6):875-86.
53. Geller JI, Argani P, Adeniran A, Hampton E, De Marzo A, Hicks J, et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer. 2008;112(7):1607-16.
54. Meyer PN, Clark JI, Flanigan RC, Picken MM. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am J Clin Pathol. 2007;128(1):70-9.
55. Rais-Bahrami S, Drabick JJ, De Marzo AM, Hicks J, Ho C, Caroe AE, et al. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. Urology. 2007;70(1):178 e3-6.
56. Dal Cin P, Stas M, Sciot R, De Wever I, Van Damme B, Van den Berghe H. Translocation (X;1) reveals metastasis 31 years after renal cell carcinoma. Cancer Genet Cytogenet. 1998;101(1):58-61.
57. Peckova K, Vanecek T, Martinek P, Spagnolo D, Kuroda N, Brunelli M, et al. Aggressive and nonaggressive translocation t(6;11) renal cell carcinoma: comparative study of 6 cases and review of the literature. Ann Diagn Pathol. 2014;18(6):351-7.
58. Damayanti NP, Budka JA, Khella HWZ, Ferris MW, Ku SY, Kauffman E, et al. Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clin Cancer Res. 2018.
59. Hou MM, Hsieh JJ, Chang NJ, Huang HY, Wang HM, Chuang CK, et al. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma. Clin Drug Investig. 2010;30(11):799-804.
60. Pwint TP, Macaulay V, Roberts IS, Sullivan M, Protheroe A. An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib. Urol Oncol. 2011;29(6):821-4.
61. Numakura K, Tsuchiya N, Yuasa T, Saito M, Obara T, Tsuruta H, et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol. 2011;16(5):577-80.
62. Malouf GG, Camparo P, Oudard S, Schleiermacher G, Theodore C, Rustine A, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol. 2010;21(9):1834-8.
63. Rua Fernandez OR, Escala Cornejo R, Navarro Martin M, Garcia Munoz M, Antunez Plaza P, Garcia Dominguez AR, et al. Renal Cell Carcinoma Associated With Xp11.2 Translocation/TFE3 Gene-fusion: A Long Response to mammalian target of rapamycin (mTOR) Inhibitors. Urology. 2018;117:41-3. | tr_TR |